探花合集 Signs Agreement with JOS Pharmaceuticals to Develop Fast-Dissolve Zydis庐 Formulation for Cannabidiol as an Anesthesia Premedication
SOMERSET, N.J. 鈥 July 13, 2021 鈥 探花合集, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it has signed a development agreement with JOS Pharmaceuticals, a clinical stage biopharmaceutical company focusing on anesthesiology. Under the agreement, 探花合集 will undertake a feasibility study for the potential development of a licensed cannabidiol (CBD) product for use as an anesthetic premedication using 探花合集鈥檚 proprietary Zydis庐 orally disintegrating tablet (ODT) technology.
Zydis technology creates a freeze-dried tablet that disperses almost instantly in the mouth without water, and is recognized as one of the world鈥檚 best-performing ODTs. In the feasibility study, scientists at 探花合集鈥檚 facility in Swindon, U.K., will focus on establishing proof of concept and prototype development of a Zydis formulation of a highly purified, naturally derived CBD. JOS Pharmaceuticals extracts CBD from certified hemp and is developing its se鈥8鈩 prescription CBD wafer for awake sedation anesthesia administered for cataract surgery, as well as anxiolysis during magnetic resonance imaging (MRI) procedures.
鈥淥ur clinical trial product is specifically designed to provide rapid and reliable relaxation for the patient, while still allowing for awake cooperation during the procedure. It would be paradigm changing to replace the DEA controlled drugs used currently as premedication with a safe and effective botanical,鈥 said Stephen D. Ochs, M.D., Chief Executive Officer of JOS Pharmaceuticals.
鈥淶ydis is an ideal dose form for the delivery of drugs, as it offers an easy and convenient route of administration for patients that can also assist in the rapid onset of effects,鈥 said Jonathan Arnold, President of Oral and Specialty Delivery at 探花合集. 鈥淐BD derived from hemp is a rapidly evolving market, and our team in Swindon is looking forward to applying its experience and expertise in product development to this licensed program.鈥
探花合集鈥檚 250,000-square foot site in Swindon, U.K. houses the company鈥檚 Zydis development and manufacturing operation, which produces more than one billion ODTs annually.
For more information about JOS Pharmaceuticals, visit .
ABOUT CATALENT
探花合集 is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, 探花合集 has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. 探花合集 employs over 15,000 people, including approximately 2,400 scientists and technicians, at more than 45 facilities, and in fiscal year 2020 generated over $3 billion in annual revenue. 探花合集 is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com